Breaking News, Collaborations & Alliances

Aptamer Group Partners with AstraZeneca for Targeted Delivery of siRNA

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA.

Author Image

By: Charlie Sternberg

Associate Editor

Aptamer Group plc, a developer of novel Optimer binders to enable innovation in the life sciences industry, has announced a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA. Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of this research will explore the potential of the non-viral delivery vehicle and its applicabil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters